Insilico Medicine has exceeded its target in Series E financing, raising a total of approximately $123 million in this round.

36Kr learned that Insilico Medicine announced that it had recently completed the full delivery of its Series E financing. The total amount raised in this round was approximately $123 million, exceeding the set target. This Series E financing was jointly led by the private equity fund under Value Partners Group, Pudong Venture Capital and Pufa Group, Wuxi Venture Capital and Yixing State-owned Assets Management, and also attracted the active participation of diversified investors in the industrial and technological fields, while continuing to receive further support from Insilico Medicine's existing global investors. In addition to the investors disclosed in the previous announcement, this round of financing also welcomed new investors such as Dacheng Investment Co., Ltd. and existing investors of Insilico Medicine such as Prosperity7 Ventures. The funds raised in this round will be used to drive Insilico Medicine's breakthroughs in the upgrade of its artificial intelligence platform and the innovation of its drug R & D pipeline.